Search our Database of Scientific Publications and Authors

I’m looking for a

    8162 results match your criteria Breast cancer research and treatment[Journal]

    1 OF 164

    Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing.
    Breast Cancer Res Treat 2017 Sep 19. Epub 2017 Sep 19.
    ARUP Laboratories, Department of Pathology, University of Utah, 500 Chipeta Way, MC 115, Salt Lake City, UT, 84108, USA.
    Purpose: Cancer antigens (CA) 15-3 and 27.29 are used in the clinical management of many breast cancer patients. Given that immunoassays for CA 15-3 and CA 27. Read More

    Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
    Breast Cancer Res Treat 2017 Sep 19. Epub 2017 Sep 19.
    Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
    Purpose: This study compares immunohistochemical (IHC) versus molecular subtyping (BluePrint and MammaPrint) in the population of patients enrolled in MINDACT and outcome based on molecular subtyping (MS) versus surrogate pathological subtyping (PS) as defined by the 2013 St. Gallen guidelines.

    Methods: MS classified patients in the following subtypes: Luminal A, Luminal B, HER-2-, and Basal-type. Read More

    Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy.
    Breast Cancer Res Treat 2017 Sep 18. Epub 2017 Sep 18.
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, San Francisco, CA, 94115, USA.
    Purpose: Chemotherapy-induced alopecia is a distressing side effect of cancer treatment. The aim of this registry study was to assess efficacy and tolerability of scalp hypothermia using Penguin Cold Caps (Penguin) in breast cancer patients.

    Methods: Hair loss was assessed by patients using a 100-point Visual Analog Scale (VAS) and by physicians using the 5-point Dean Scale at baseline, every 3-4 weeks during chemotherapy, and at least 1 month after completion of chemotherapy. Read More

    Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008.
    Breast Cancer Res Treat 2017 Sep 16. Epub 2017 Sep 16.
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans St., Baltimore, MD, 21287, USA.
    Background: Methylated gene markers have shown promise in predicting breast cancer outcomes and treatment response. We evaluated whether baseline and changes in tissue and serum methylation levels would predict pathological complete response (pCR) in patients with HER2-negative early breast cancer undergoing preoperative chemotherapy.

    Methods: The TBCRC008 trial investigated pCR following 12 weeks of preoperative carboplatin and albumin-bound paclitaxel + vorinostat/placebo (n = 62). Read More

    Characteristics and prognosis of breast cancer after liver or kidney transplantation.
    Breast Cancer Res Treat 2017 Sep 15. Epub 2017 Sep 15.
    Division of Breast and Endocrine Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Pungnap-2dong, Song pa Gu, Seoul, 05505, Korea.
    Purpose: Immunoediting is crucial in cancer development and progression. This study compared the characteristics and prognosis of post-transplant breast cancer (PTBC) patients receiving immunosuppressants and general breast cancer patients.

    Methods: Data from the Asan Medical Center Breast Cancer (AMCBC), kidney transplantation, and liver transplantation databases recorded during 1989-2013 were retrospectively analyzed. Read More

    The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
    Breast Cancer Res Treat 2017 Sep 15. Epub 2017 Sep 15.
    Women's College Research Institute, Women's College Hospital, 76 Grenville Street, 6th Floor, Toronto, ON, M5S 1B2, Canada.
    Purpose: Preventive breast surgery is offered to unaffected BRCA mutation carriers to prevent breast cancer incidence and mortality. The clinical benefit of preventive mastectomy can be measured in several ways, including extension of life expectancy (mean years of life gained) and by estimating the probability of surviving until age 80. We sought to estimate the expected benefit of a preventive mastectomy at various ages, using these indices of mortality, by simulating hypothetical cohorts of women. Read More

    Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
    Breast Cancer Res Treat 2017 Sep 14. Epub 2017 Sep 14.
    Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
    Background: Given its high recurrence risk, guidelines recommend systemic therapy for most patients with early-stage triple-negative breast cancer (TNBC). While some clinicopathologic factors and tumor-infiltrating lymphocytes (TILs) are known to be prognostic in patients receiving chemotherapy, their prognostic implications in systemically untreated patients remain unknown.

    Methods: From a cohort of 9982 women with surgically treated non-metastatic breast cancer, all patients with clinically reported ER-negative/borderline (≤10%) disease were selected for central assessment of ER/PR/HER2, histopathology, Ki-67, and TILs. Read More

    Molecular profile of atypical hyperplasia of the breast.
    Breast Cancer Res Treat 2017 Sep 14. Epub 2017 Sep 14.
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
    Purpose: Atypical ductal and atypical lobular hyperplasia (AH) of the breast are important proliferative lesions which are associated with a significantly increased risk for breast cancer. The breast cancer which develops in association with AH may occur synchronously, representing local progression, or metachronously at a later date in either the ipsilateral or contralateral breast. These high-risk characteristics of AH suggest they contain significant genomic changes. Read More

    Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients.
    Breast Cancer Res Treat 2017 Sep 14. Epub 2017 Sep 14.
    Human Genotyping Unit-CeGen, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Melchor Fernández Almagro 3, 28029, Madrid, Spain.
    Purpose: Anthracyclines are widely used chemotherapeutic drugs that can cause progressive and irreversible cardiac damage and fatal heart failure. Several genetic variants associated with anthracycline-induced cardiotoxicity (AIC) have been identified, but they explain only a small proportion of the interindividual differences in AIC susceptibility.

    Methods: In this study, we evaluated the association of low-frequency variants with risk of chronic AIC using the Illumina HumanExome BeadChip array in a discovery cohort of 61 anthracycline-treated breast cancer patients with replication in a second independent cohort of 83 anthracycline-treated pediatric cancer patients, using gene-based tests (SKAT-O). Read More

    Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?
    Breast Cancer Res Treat 2017 Sep 14. Epub 2017 Sep 14.
    Division of Hematology/Oncology, School of Medicine, University of North Carolina at Chapel Hill, 170 Manning Drive, Campus Box 7305, Chapel Hill, NC, 27599-7305, USA.
    Purpose: This study investigates weight trajectories in pre- versus postmenopausal breast cancer (BC) survivors diagnosed with hormone receptor-positive tumors, with a specific focus on discerning menopausal status and type of endocrine treatment (ET) as risk factors for weight gain during ET.

    Methods: We conducted a retrospective review of electronic medical records. Descriptive statistics and Chi-squared and t tests were used to compare pre- and postmenopausal women. Read More

    Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective.
    Breast Cancer Res Treat 2017 Sep 14. Epub 2017 Sep 14.
    Department of Pharmacy, Maccabi Healthcare Services, 27 Hamered St., 68125, Tel Aviv, Israel.
    Purpose: To evaluate the association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer (BC) risk.

    Methods: A cohort of all Maccabi Healthcare Services (MHS) female members aged 40-50 years between 1/2003 and 12/2013 was used to identify LNG-IUS users as "cases," and 2 age-matched non-users as "controls." Exclusion criteria included: prior BC diagnosis, prior (5 years pre-study) and subsequent treatment with other female hormones or prophylactic tamoxifen. Read More

    Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
    Breast Cancer Res Treat 2017 Sep 13. Epub 2017 Sep 13.
    Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
    Purpose: The present study evaluated whether morphological-measured stromal and intra-tumour tumour-infiltrating lymphocytes (TILs) levels were associated with gene expression profiles, and whether TILs-associated genomic signature (GS) could be used to predict clinical outcomes and response to therapies in several breast cancer subtypes.

    Methods: We retrospectively evaluated haematoxylin eosin (HE)-TILs levels and gene expression profiling data from 40 patients with primary breast cancer and extracted the 22 overexpressed genes in cases with high TILs scores as the TILs-GS. The TILs-GS were compared with breast cancer subtype and were evaluated predictive values for prognosis and response to therapies. Read More

    Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing.
    Breast Cancer Res Treat 2017 Sep 13. Epub 2017 Sep 13.
    Department of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, 2-2-E10 Yamadaoka, Suita, Osaka, 565-0871, Japan.
    Purpose: We aimed to develop a highly sensitive method to detect ESR1 mutations in cell-free DNA (cfDNA) using next-generation sequencing with molecular barcode (MB-NGS) targeting the hotspot segment (c.1600-1713).

    Methods: The sensitivity of MB-NGS was tested using serially diluted ESR1 mutant DNA and then cfDNA samples from 34 patients with metastatic breast cancer were analyzed with MB-NGS. Read More

    Take care of your neighborhood.
    Breast Cancer Res Treat 2017 Sep 12. Epub 2017 Sep 12.
    Washington Cancer Institute, MedStar Washington Hospital Center, 110 Irving Street NW, Washington, DC, 20010, USA.
    Purpose: Urban women in certain Washington, DC neighborhoods present with advanced breast cancer at high rates despite access to health insurance and health care.

    Methods: Through a two-phase intervention, community health workers (CHWs) educated and surveyed individuals regarding healthcare utilization and breast health and cancer awareness. In phase I, CHWs educated and administered a survey to 1092 women, of whom 95. Read More

    Healthcare utilization, Medicare spending, and sources of patient distress identified during implementation of a lay navigation program for older patients with breast cancer.
    Breast Cancer Res Treat 2017 Sep 12. Epub 2017 Sep 12.
    UAB Comprehensive Cancer Center, University of Alabama at Birmingham (UAB), Birmingham, AL, USA.
    Purpose: Despite benefits for patients, sustainability of breast cancer navigation programs is challenging due to the lack of reimbursement for navigators. This analysis describes distress reported by breast cancer patients to navigators and the impact of navigation on healthcare utilization for older adults with breast cancer.

    Methods: We conducted a retrospective cohort study of Medicare administrative claims data and patient-reported distress assessments. Read More

    Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.
    Breast Cancer Res Treat 2017 Sep 11. Epub 2017 Sep 11.
    Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
    Purpose: Though advanced and metastatic epidermal growth factor receptor 2 (HER2)-positive disease is not curable, a small proportion of patients with HER2-positive metastatic breast cancer remain in prolonged complete remission with anti-HER2 treatment. We hypothesized that some cases of HER2-positive metastatic breast cancer may be curable. In this large, multicenter retrospective study, we aimed to assess the long-term outcomes for patients with a durable response to trastuzumab. Read More

    Severe depression more common in patients with ductal carcinoma in situ than early-stage invasive breast cancer patients.
    Breast Cancer Res Treat 2017 Sep 11. Epub 2017 Sep 11.
    Imaging Division, University Medical Center Utrecht, Utrecht, The Netherlands.
    Purpose: Ductal carcinoma in situ (DCIS) is associated with an excellent prognosis; historical studies have shown similar levels of psychological distress in patients with DCIS and with early-stage invasive breast cancer (early-IBC). It is suggested that these results might have led to better patient education about prognosis after DCIS. This study reports the current levels of anxiety, depression, and health-related quality of life (HRQoL) in DCIS and early-IBC patients. Read More

    Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
    Breast Cancer Res Treat 2017 Sep 9. Epub 2017 Sep 9.
    Faculty of Medicine, The University of Queensland, Herston, QLD, Australia.
    Purpose: Cell lines are extremely useful tools in breast cancer research. Their key benefits include a high degree of control over experimental variables and reproducibility. However, the advantages must be balanced against the limitations of modelling such a complex disease in vitro. Read More


    Socioeconomic status and breast cancer treatment.
    Breast Cancer Res Treat 2017 Sep 7. Epub 2017 Sep 7.
    Department of Medicine and Center for Patient Care and Outcomes Research, Medical College of Wisconsin, 8701 Watertown Plank Road, Suite H3100, Milwaukee, WI, 53226, USA.
    Purpose: Evidence suggests substantial disparities in breast cancer survival by socioeconomic status (SES). We examine the extent to which receipt of newer, less invasive, or more effective treatments-a plausible source of disparities in survival-varies by SES among elderly women with early-stage breast cancer.

    Methods: Multivariate regression analyses applied to 11,368 women (age 66-90 years) identified from SEER-Medicare as having invasive breast cancer diagnosed in 2006-2009. Read More

    Second opinion strategies in breast pathology: a decision analysis addressing over-treatment, under-treatment, and care costs.
    Breast Cancer Res Treat 2017 Sep 6. Epub 2017 Sep 6.
    Department of Pathology, UVM Cancer Center, University of Vermont, Burlington, VT, USA.
    Purpose: To estimate the potential near-term population impact of alternative second opinion breast biopsy pathology interpretation strategies.

    Methods: Decision analysis examining 12-month outcomes of breast biopsy for nine breast pathology interpretation strategies in the U.S. Read More

    An observational study investigating failure of primary endocrine therapy for operable breast cancer in the elderly.
    Breast Cancer Res Treat 2017 Sep 6. Epub 2017 Sep 6.
    Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK.
    Background: Elderly patients are more likely to have oestrogen receptor positive cancers that can be treated without surgery with primary endocrine therapy (PET). Few studies have sought to identify predictors of failure of PET and so the aim of this study was to evaluate treatment failures in elderly breast cancer patients treated with PET and to determine predictors of failure.

    Methods: A retrospective observational study was performed on consecutive patients with ER-positive early stage breast cancer treated with PET between 2005 and 2015 in the three breast units in the North East of England. Read More

    Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
    Breast Cancer Res Treat 2017 Sep 5. Epub 2017 Sep 5.
    German Breast Group, c/o GBG Forschungs GmbH, Martin-Behaim-Straße 12, 63263, Neu-Isenburg, Germany.
    Purpose: The estrogen receptor (ER) is involved in control of progesterone receptor (PgR) expression and lack of PgR may be also a surrogate of altered growth factor signaling. The aim of this study was therefore to investigate PgR expression as predictive factor for response to neoadjuvant therapy and long-term outcome.

    Methods: Five thousand and six hundred and thirteen patients with primary breast cancer and positive ER expression from ten German neoadjuvant trials of anthracycline and taxane-based chemotherapy were included. Read More


    Association of the severity of diabetes-related complications with stage of breast cancer at diagnosis among elderly women with pre-existing diabetes.
    Breast Cancer Res Treat 2017 Sep 2. Epub 2017 Sep 2.
    Department of Pharmaceutical Systems and Policy, School of Pharmacy, West Virginia University, Morgantown, WV, USA.
    Purpose: This study assessed the association between the severity of diabetes complications using diabetes complications severity index (DCSI) and stage of breast cancer (BC) at diagnosis among elderly women with pre-existing diabetes and incident BC.

    Methods: Using Surveillance, Epidemiology and End Results-Medicare data, we identified women with incident BC during 2004-2011 and pre-existing diabetes (N = 7729). Chi-square tests were used to test for group differences in stage of BC at diagnosis. Read More

    Inverse relationship between Ki67 and survival in early luminal breast cancer: confirmation in a multivariate analysis.
    Breast Cancer Res Treat 2017 Sep 1. Epub 2017 Sep 1.
    Department of Pathology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Sant Quinti 87-89, 08041, Barcelona, Spain.
    Introduction: Ki67 is a prognostic marker in early breast cancer, but its real usefulness remains controversial. The standard cut-off values for Ki67 have not been universally accepted and different values may be used depending on the type of biopsy (fine needle biopsy versus surgical specimen biopsy). The objective of this study was to evaluate the prognostic significance of Ki67 and to determine the most accurate prognostic cut-off. Read More

    Healthy lifestyle impact on breast cancer-specific and all-cause mortality.
    Breast Cancer Res Treat 2017 Aug 31. Epub 2017 Aug 31.
    Department of Epidemiology and Population Health, School of Public Health and Information Sciences, James Graham Brown Cancer Center, University of Louisville, 485 E. Gray St., Louisville, KY, 40202, USA.
    Purpose: While several studies have evaluated the association of combined lifestyle factors on breast cancer-specific mortality, few have included Hispanic women. We constructed a "healthy behavior index" (HBI) and evaluated its associations with mortality in non-Hispanic White (NHW) and Hispanic women diagnosed with breast cancer from the southwestern U.S. Read More

    Non-visualized sentinel nodes in breast cancer patients; prevalence, risk factors, and prognosis.
    Breast Cancer Res Treat 2017 Aug 31. Epub 2017 Aug 31.
    Department of Surgery, Máxima Medical Center, Veldhoven, The Netherlands.
    Background: Evidence and consensus is lacking in international guidelines regarding axillary treatment recommendations for patients in whom a sentinel lymph node (SLN) cannot be visualized (non-vSLN) during the sentinel node procedure. In this study we aimed to determine the prevalence of non-vSLNs in a Dutch population of breast cancer patients and to examine predictors and survival rate for non-vSLN.

    Methods: A nationwide, retrospective, population-based study was performed including 116,920 patients with invasive breast cancer who underwent a SLN procedure in the Netherlands between January 2005 and December 2013. Read More

    BMI change and abdominal circumference are risk factors for breast cancer, even in Asian women.
    Breast Cancer Res Treat 2017 Aug 31. Epub 2017 Aug 31.
    Department of Breast Cancer, St. Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo, 104-8560, Japan.
    Purpose: We investigated the association between breast cancer incidence and obesity among Asian women.

    Methods: We used data from 30,109 women who had undergone medical check-ups and opportunistic breast cancer screening at least twice at the St. Luke's International Hospital Affiliated Clinic, Center for Preventive Medicine, between April 1, 2005 and March 31, 2014. Read More

    Chronic pain and other symptoms among breast cancer survivors: prevalence, predictors, and effects on quality of life.
    Breast Cancer Res Treat 2017 Aug 31. Epub 2017 Aug 31.
    School of Public Health, University of Haifa, Haifa, Israel.
    Purpose: To investigate prevalence and risk factors associated with self-reported chronic pain, and other symptoms related to breast cancer or its treatment among breast cancer survivors (BCS).

    Methods: A cross-sectional study of a random sample of 410 female BCS, members of "Leumit" healthcare fund, diagnosed with primary nonmetastatic invasive breast cancer in the years 2002-2012. The study questionnaire included questions on health-related quality of life, pain symptoms, and was completed by all women contacted. Read More

    Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines.
    Breast Cancer Res Treat 2017 Aug 31. Epub 2017 Aug 31.
    Department of Pathology and Laboratory Medicine, Guangdong General Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Lu, Guangzhou, 510080, China.
    Purpose: The updated 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing have made some major changes in HER2 fluorescence in situ hybridization (FISH) interpretation criteria with additional FISH equivocal cases. Repeat HER2 testing is recommended after initial HER2 FISH equivocal results; however, little is known about its impact on final HER2 status. The aim of this study is to investigate whether reflex test clarifies HER2 status, and to characterize clinicopathological features of the newly defined HER2 equivocal group. Read More

    African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages.
    Breast Cancer Res Treat 2017 Aug 30. Epub 2017 Aug 30.
    Department of Pathology and Laboratory Medicine, Emory University, 1364 Clifton Road, Suite H175, Atlanta, GA, 30322, USA.
    Purpose: Racial disparity of breast cancer in each subtype and substage is not clear.

    Methods: We reviewed 156,938 patients with breast cancer from 2010 to 2012 from the National Cancer Institute Surveillance, Epidemiology, and End Results database. Breast cancer was subtyped by hormone receptor (HR) and human epidermal growth factor 2 (HER2) status as HR+/HER2-, HR+/HER2+, HR-/HER2+, and HR-/HER2-. Read More

    Obesity, physical activity, and breast cancer survival among older breast cancer survivors in the Cancer Prevention Study-II Nutrition Cohort.
    Breast Cancer Res Treat 2017 Aug 31. Epub 2017 Aug 31.
    Epidemiology Research Program, American Cancer Society, Atlanta, GA, USA.
    Purpose: Nearly half of the 3.5 million female breast cancer survivors in the US are aged 65 years or older at diagnosis, yet little is known about associations of obesity and physical activity with breast cancer-specific mortality (BCSM) among older survivors.

    Methods: Between 1992 and 2013, 5254 women in the Cancer Prevention Study-II Nutrition Cohort were diagnosed with local or regional breast cancer among whom 1771 deaths (505 breast cancer deaths) occurred. Read More

    Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution.
    Breast Cancer Res Treat 2017 Aug 29. Epub 2017 Aug 29.
    Division of Breast Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
    Purpose: In the management of estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer (ER+HER2-MBC) patients, endocrine therapy (ET) is preferred to chemotherapy (CT) as a primary systemic therapy (PST) when tumor burden is not high. However, there are no definite criteria for choosing a PST, transitioning from ET to CT or using maintenance ET subsequent to CT.

    Methods: We reviewed the medical records of 311 ER+HER2-MBC patients who underwent CT from September 2002 to December 2016 and assessed their outcomes. Read More

    ATM is required for SOD2 expression and homeostasis within the mammary gland.
    Breast Cancer Res Treat 2017 Aug 28. Epub 2017 Aug 28.
    Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, 1600 SW Archer Road, Box 1000245, Gainesville, FL, 32610, USA.
    Purpose: ATM activates the NF-κB transcriptional complex in response to genotoxic and oxidative stress. The purpose of this study was to examine if the NF-κB target gene and critical antioxidant SOD2 (MnSOD) in cultured mammary epithelium is also ATM-dependent, and what phenotypes arise from deletion of ATM and SOD2 within the mammary gland.

    Methods: SOD2 expression was studied in human mammary epithelial cells and MCF10A using RNAi to knockdown ATM or the NF-κB subunit RelA. Read More

    Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.
    Breast Cancer Res Treat 2017 Aug 24. Epub 2017 Aug 24.
    Lung Cancer Site Disease Group, Sylvester Comprehensive Cancer Center, University of Miami and the Miller School of Medicine, Miami, USA.
    Purpose: Breast cancer is the most common malignancy among women in Mexico. A large proportion of Mexican patients present with advanced disease, and 25% have HER2-positive tumors. We performed a cost-effectiveness analysis of different sequencing strategies of HER2-targeted agents in Mexico according to various payer perspectives. Read More

    Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families.
    Breast Cancer Res Treat 2017 Aug 24. Epub 2017 Aug 24.
    QIMR Berghofer, Brisbane, QLD, 4006, Australia.
    Purpose: The main aim of this study was to screen epigenetic modifier genes and known breast cancer driver genes for germline mutations in non-BRCA1/2 (BRCAx) breast cancer families in order to identify novel susceptibility genes of moderate-high penetrance.

    Methods: We screened 264 candidate susceptibility genes in 656 index cases from non-BRCA1/2 families. Potentially pathogenic candidate mutations were then genotyped in all available family members for the assessment of co-segregation of the variant with disease in the family in order to estimate the breast cancer risks associated with these mutations. Read More

    Familial associations of male breast cancer with other cancers.
    Breast Cancer Res Treat 2017 Aug 23. Epub 2017 Aug 23.
    Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120, Heidelberg, Germany.
    Purpose: Male breast cancer is associated with female breast cancer in families but whether male breast cancer clusters with other discordant cancers has not been studied. As concordant male breast cancers are utterly rare, discordant associations of male breast cancer with other cancers may reveal genetic and possible environmental risk factors contributing to male breast cancer susceptibility.

    Methods: We calculated relative risks (RRs) for male breast cancer in families with discordant cancers, and conversely, for discordant cancers in families of male breast cancer patients, based on 15. Read More

    Increased risk of arterial thromboembolism in older men with breast cancer.
    Breast Cancer Res Treat 2017 Aug 23. Epub 2017 Aug 23.
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 485 Lexington Avenue, 2nd Floor, New York, NY, 10017, USA.
    Purpose: Male breast cancer is a rare and understudied disease predominantly affecting men over age 60. Risk of arterial thromboembolic events (ATE) in men increases with age. We examined ATE risk following primary breast cancer diagnosis in elderly men. Read More

    Performance characteristics of specimen radiography for margin assessment for ductal carcinoma in situ: a systematic review.
    Breast Cancer Res Treat 2017 Aug 22. Epub 2017 Aug 22.
    Department of Surgery, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 SB, Nijmegen, The Netherlands.
    Background: Reducing positive margin rate (PMR) and reoperation rate in breast-conserving operations remains a challenge, mainly regarding ductal carcinoma in situ (DCIS). Intra-operative margin assessment tools have emerged to reduce PMR over the last decades, including specimen radiography (SR). No consensus has been reached on the reliability and efficacy of SR in DCIS. Read More

    Thrombocytosis as a prognostic factor in inflammatory breast cancer.
    Breast Cancer Res Treat 2017 Aug 22. Epub 2017 Aug 22.
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1220 Holcombe Blvd, Houston, TX, 77030, USA.
    Purpose: Platelets are essential components of hemostasis and also play an important role in the tumor microenvironment. The purposes of our research were to examine the role of thrombocytosis in inflammatory breast cancer (IBC) and to know which cytokine drives thrombocytosis.

    Methods: We reviewed the medical records of 3654 patients with stage I-III breast cancer treated between 1998 and 2013, including 230 patients (6%) with IBC. Read More

    Effects of cytokines derived from cancer-associated fibroblasts on androgen synthetic enzymes in estrogen receptor-negative breast carcinoma.
    Breast Cancer Res Treat 2017 Aug 22. Epub 2017 Aug 22.
    Department of Pathology, Tohoku University Graduate School of Medicine, 2-1, Seiryo-machi, Aoba-Ku, Sendai-shi, Miyagi, 980-8575, Japan.
    Purpose: The tumor microenvironment plays pivotal roles in promotion of many malignancies. Cancer-associated fibroblasts (CAFs) have been well-known to promote proliferation, angiogenesis, and metastasis but mechanistic understanding of tumor-stroma interactions is not yet complete. Recently, estrogen synthetic enzymes were reported to be upregulated by co-culture with stromal cells in ER positive breast carcinoma (BC) but effects of co-culture on androgen metabolism have not been extensively examined. Read More

    Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society.
    Breast Cancer Res Treat 2017 Aug 22. Epub 2017 Aug 22.
    Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 5th floor Breast-endocrine, Irwon-ro 81, Gangnam-gu, Seoul, 06351, South Korea.
    Purpose: Numerous studies have demonstrated that breast cancer in young women (BCY) has unfavorable prognostic features and more unfavorable subtypes. However, few studies have evaluated the effect of subtype disparities on breast cancer prognosis by age, especially for BCY. We analyzed breast cancer mortality stratified by tumor subtype according to age among patients younger than 50 years. Read More

    Survival and level of care among breast cancer patients with brain metastases treated with whole brain radiotherapy.
    Breast Cancer Res Treat 2017 Aug 22. Epub 2017 Aug 22.
    Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institute Solna, Karolinska University Hospital, 171 76, Stockholm, Sweden.
    Purpose: The benefit of whole brain radiotherapy (WBRT) for late stage breast cancer patients with brain metastases has been questioned. In this study we evaluated survival and level of care (hospital or home) following WBRT in a population-based cohort by personal and tumor characteristics.

    Methods: We identified 241 consecutive patients with breast cancer and brain metastases receiving WBRT in Stockholm, Sweden, 1999-2012. Read More

    Utilization of bioimpedance spectroscopy in the prevention of chronic breast cancer-related lymphedema.
    Breast Cancer Res Treat 2017 Aug 22. Epub 2017 Aug 22.
    Breast Care Specialists, Bethpage, NY, USA.
    Background: This analysis was performed to assess the impact of early intervention following prospective surveillance using bioimpedance spectroscopy (BIS) to detect and manage breast cancer-related lymphedema (BCRL).

    Methods: From 8/2010 to 12/2016, 206 consecutive patients were evaluated with BIS. The protocol included pre-operative assessment with L-Dex as well as post-operative assessments at regular intervals. Read More

    1 OF 164